PMOS
Published in the prestigious medical journal *The Lancet*, this global consensus marks a new era in understanding and treating this complex condition.
Why Was the Name Changed to PMOS?
For decades, the old name (PCOS) caused significant confusion for both patients and healthcare providers. It narrowly focused on "cysts on the ovaries," which is scientifically inaccurate since these are actually underdeveloped follicles, not true cysts.
The new term PMOS accurately reflects the true, systemic nature of the disorder. It highlights that this is not merely a localized reproductive issue, but a broad endocrine and metabolic (Metabolic) disorder that impacts a woman's entire hormonal ecosystem and overall health.
Key Symptoms of PMOS
PMOS affects approximately 170 million women worldwide (about 1 in 8 women of reproductive age). The symptoms are diverse, spanning metabolic, physical, and psychological aspects, including:
- Irregular Periods: Infrequent, unpredictable, or completely absent menstrual cycles due to anovulation.
- Hyperandrogenism Features: Severe acne, thinning scalp hair (male-pattern baldness), and excess facial or body hair (hirsutism).
- Metabolic & Weight Issues: Weight gain and extreme difficulty losing weight due to underlying insulin resistance.
- Skin Changes: Darkened skin patches (acanthosis nigricans) around the neck or body folds, and skin tags.
- Fertility Challenges: PMOS remains one of the leading causes of ovulatory infertility worldwide.
Long-Term Health Risks Associated with PMOS
Emphasizing the "Metabolic" aspect in the new PMOS acronym is crucial for raising awareness about long-term chronic risks that go far beyond fertility, such as:
- A significantly higher risk of developing Type 2 diabetes.
- Increased susceptibility to cardiovascular diseases, high blood pressure, and stroke.
- Mental health struggles, including severe anxiety and depression, driven by both hormonal fluctuations and body image changes.
- Pregnancy complications like gestational diabetes or premature birth.
Managing PMOS and the Future of Treatment
According to international experts, the first line of defense for managing PMOS focuses heavily on lifestyle interventions. This includes a balanced, low-glycemic diet, regular physical activity, and optimizing sleep to reduce high insulin levels, which trigger the ovaries to produce excess testosterone.
Medical treatments also include insulin-sensitizing medications (such as Metformin), hormonal contraceptives to regulate cycles, and anti-androgen therapies to control hirsutism and acne.
Conclusion
The official transition to PMOS is not just a change in medical jargon; it is a vital step toward improving diagnostic accuracy, reducing disease stigma, and providing holistic care that addresses the hormonal, metabolic, and mental health needs of patients. A 3-year transition plan is currently underway to implement this name globally across all clinical guidelines by 2028.
